The state of Louisiana currently has 6 active clinical trials seeking participants for Pulmonary Fibrosis research studies. These trials are conducted in various cities, including New Orleans, Baton Rouge, Shreveport and Metairie.
Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
Recruiting
A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
03/15/2024
Locations: Tulane Medical Center, New Orleans, Louisiana
Conditions: Idiopathic Pulmonary Fibrosis
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Recruiting
Study RIN-PF-301 is designed to evaluate the superiority of inhaled treprostinil against placebo for the change in absolute forced vital capacity (FVC) from baseline to Week 52.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/01/2024
Locations: LSU Health Sciences Center New Orleans, New Orleans, Louisiana +2 locations
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
Recruiting
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/23/2024
Locations: Tulane University School of Medicine, New Orleans, Louisiana
Conditions: Idiopathic Pulmonary Fibrosis
A Study to Investigate Leramistat in Patients With IPF
Recruiting
To compare the effect of daily oral dosing of leramistat over 12 weeks with placebo in participants aged 40 years or older with idiopathic pulmonary fibrosis (IPF).
Gender:
All
Ages:
40 years and above
Trial Updated:
02/16/2024
Locations: Benchmark Research - Covington - HyperCore - PPDS, Covington, Louisiana
Conditions: Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Recruiting
This registry will collect data on the strategies used to achieve a diagnosis of Idiopathic Pulmonary Fibrosis (IPF) and Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype (ILD) and the treatment and management efforts applied throughout study follow-up, clinical outcome events and patient reported outcome data. Blood samples will be collected periodically throughout the study for use in future research efforts. For participants with non-IPF, chronic fibrosing ILD with progre... Read More
Gender:
All
Ages:
30 years and above
Trial Updated:
11/24/2023
Locations: Tulane University, New Orleans, Louisiana
Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
Recruiting
A placebo-controlled, multicenter, randomized trial to test GKT137831 in ambulatory patients with idiopathic pulmonary fibrosis. This drug is an inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) isoforms. The investigators hypothesize the drug will decrease pulmonary injury due to reactive oxygen species (ROS) generated by NOX enzymes, which are believed to play an important role in the development of IPF. Treatment with GKT137831 could result in significant benefit... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
07/11/2023
Locations: Tulane University Medical Center, New Orleans, Louisiana
Conditions: Idiopathic Pulmonary Fibrosis